Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy

  title={Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy},
  author={Min Chen and Thiruma V. Arumugam and Gayeshika Leanage and Quang Minh Tieng and Ashwin Yadav and Jeremy F. P. Ullmann and David She and Vy Truong and Marc J. Ruitenberg and David C. Reutens},
  journal={Scientific Reports},
Novel therapies that prevent or modify the development of epilepsy following an initiating brain insult could significantly reduce the burden of this disease. In light of evidence that immune mechanisms play an important role in generating and maintaining the epileptic condition, we evaluated the effect of a well-established immunomodulatory treatment, intravenous immunoglobulin (IVIg), on the development of epilepsy in an experimental model of epileptogenesis. In separate experiments, IVIg was… 
Complement in the development of post-traumatic epilepsy: prospects for drug repurposing.
Findings on complement activation in experimental TBI and epilepsy models are summarized, highlighting the potential of drug repurposing in the development of therapeutics to ameliorate post-traumatic epileptogenesis.
Neuroinflammatory Nexus of Pediatric Epilepsy.
A brief review of key inflammatory mediators that have become prominent in recent literature of epilepsy, including newly characterized microRNAs and their potential role in neuroinflammatory signaling are focused on.
How to Find Candidate Drug-targets for Antiepileptogenic Therapy?
The present review will introduce potential novel candidate drug-targets for AEGDs based on the published studies and provide a number of interesting sites for antiepileptogenic drugs (AEGDs).
It is concluded that anti-inflammatory and immunomodulatory drugs have a positive role to decrease the bouts of epilepsy and limit it and can be effective in improving the outcomes of patients with refractory epilepsy and status epilepticus.
Therapeutic effects of scoparone on pilocarpine (Pilo)-induced seizures in mice.
Intravenous Immunoglobulin in the Treatment of Alternating Hemiplegia of Childhood.
The definite role of IVIG in the treatment of AHC cannot be extrapolated from this report, but further prospective controlled studies should be done because of the recent discovery of the connection between an anti-inflammatory hormone (Oubain) and Na/K ATPase.
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Evidence for both beneficial and detrimental effects of complement components and activation products in multiple neurodegenerative disorders are reviewed, as well as the recent studies that support the possibility of successful pharmacological approaches to suppress excessive and detrimental complement-mediated chronic inflammation.
Modified recombinant human IgG1‐Fc is superior to natural intravenous immunoglobulin at inhibiting immune‐mediated demyelination
Findings show that recombinant biomimetics can be made that are at least two hundred‐fold more effective than IVIG in controlling demyelination by anti‐MOG antibodies.
The effects of human immunoglobulin G on enhancing tissue protection and neurobehavioral recovery after traumatic cervical spinal cord injury are mediated through the neurovascular unit
HIgG (2 g/kg) is a promising therapeutic approach to mitigate secondary pathology in SCI through antagonizing immune cell infiltration at the level of the neurovascular unit and led to greater tissue preservation, functional blood flow, and neurobehavioral recovery at 6 weeks post-SCI.


Prevention or Modification of Epileptogenesis after Brain Insults: Experimental Approaches and Translational Research
Two ongoing clinical trials will address the antiepileptogenic potential of topiramate and levetiracetam in patients with traumatic brain injury, hopefully translating laboratory discoveries into successful therapies.
Brain Inflammation in Epilepsy: Experimental and Clinical Evidence
The possibility that inflammation may be a common factor contributing, or predisposing, to the occurrence of seizures and cell death, in various forms of epilepsy of different etiologies is discussed.
Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy
Objective: To study the immediate and chronic effects of high-dose, long-term human IV immunoglobulin (hIVIg) therapy in two patients with advanced adult-onset Rasmussen’s encephalitis (RE).
MRI changes and complement activation correlate with epileptogenicity in a mouse model of temporal lobe epilepsy
MRI changes were dynamic, reflecting different outcomes in relation to the development of epilepsy, andarent diffusion coefficient changes in the hippocampus at 7 days post-SE correlated with the severity of the evolving epilepsy.
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease
It is demonstrated that IVIG promotes recognition and removal of natively formed brain Aβ deposits by primary microglia involving natural Aβ Abs in IVIG, which may have therapeutic relevance in vivo as IVIG penetrates through the blood-brain barrier and specifically binds to A β deposits in brain parenchyma.
Epilepsy and brain inflammation
Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease
Results observed in the chronic and in the acute phase associate IVIg treatment with a favourable outcome in T. cruzi infection.
Transient and chronic seizure‐induced inflammation in human focal epilepsy
PET scans in a patient with frontal epilepsy after a seizure and during a seizure‐free period provide new information about transient and chronic neuroinflammation in human epilepsy and may be relevant to understanding the process of epileptogenesis and guiding therapy.
Successful Treatment of Acute Autoimmune Limbic Encephalitis With Negative VGKC and NMDAR Antibodies
  • A. Modoni, M. Masciullo, G. Silvestri
  • Medicine, Biology
    Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
  • 2009
Previous observations of “seronegative” autoimmune LE are confirmed, suggesting the presence of other, still unknown central nervous system antigens representing a target of a postinfectious, autoimmune response in these patients.